Use of the anemia drugs Aranesp and Epogen, made by Thousand Oaks-based Amgen Inc., and Procrit, sold by Johnson & Johnson, will be reviewed by U.S. government health insurance programs.
The study of the drugs for uses other than end-stage renal diseases was announced by the Centers for Medicare and Medicaid Services.
